ApprovalTrail

Approval · Notice of Compliance 21021 · 2018

OLIMEL 3.3 E: Notice of Compliance 21021

Issued June 26, 2018

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
21021
Date
June 26, 2018
Company
Baxter CorporationMississauga, Ontario, Canada
Product type
Nonprescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
To add a new 7.6% and 7.6% E (with electrolytes) strengths to the olimel product line

Products in this notice

BrandDINStatus today
OLIMEL 3.3 ENot yet assigned—
OLIMEL 4.4%Not yet assigned—
OLIMEL 4.4% ENot yet assigned—
OLIMEL 5.7%Not yet assigned—
OLIMEL 5.7% ENot yet assigned—
OLIMEL 7.6%02477947Marketed
OLIMEL 7.6% E02477955Marketed
PERIOLIMEL 2.5% ENot yet assigned—

Medicinal ingredients